Amarin Corp Plc (AMRN)

[sstyles]

Don't let today's share price fool you. The past two events: GSK ruling and our case vs Hikma and HealthNet, which is ongoing, have shifted the calculus in a major way against the generics.

We now have the GSK ruling which we can use as a precedential case to help us and we have certain facts from our case which we know to be true: generics did not have a CV limitation on their label.

Moreover, the lawyers for Healthnet are probably thinking Hikma what have you dragged us into.

This is huge for Amarin. It may take a few days for the market to figure it out but the landscape for the generics has shifted in a major way.

The more the generics try to creep up and obtain more than the very high TG market the more it will only hurt them in the end by further proving infringement on the CV indication. This GSK ruling is huge.

And btw: the CAFC has indicated no en banc hearing. Sorry Teva you lose.